Nothing Special   »   [go: up one dir, main page]

US9034382B2 - Oseltamivir phosphate granule and preparation method thereof - Google Patents

Oseltamivir phosphate granule and preparation method thereof Download PDF

Info

Publication number
US9034382B2
US9034382B2 US12/225,935 US22593506A US9034382B2 US 9034382 B2 US9034382 B2 US 9034382B2 US 22593506 A US22593506 A US 22593506A US 9034382 B2 US9034382 B2 US 9034382B2
Authority
US
United States
Prior art keywords
granules
oseltamivir phosphate
oseltamivir
dried
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/225,935
Other versions
US20090176877A1 (en
Inventor
Song Li
Wu Zhong
Junhai Xiao
Yunde Xie
Xingzhou Li
Hao Cui
Zhibing Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Assigned to INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA reassignment INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CUI, HAO, LI, SONG, LI, XINGZHOU, XIAO, JUNHAI, XIE, YUNDE, ZHENG, ZHIBING, ZHONG, WU
Publication of US20090176877A1 publication Critical patent/US20090176877A1/en
Application granted granted Critical
Publication of US9034382B2 publication Critical patent/US9034382B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to oseltamivir phosphate granules and preparation method thereof.
  • Neuramidinase (NA) inhibitor is an anti-flu virus drug that has been developed recently.
  • NA inhibitor As a recently developed NA inhibitor, oseltamivir phosphate is effective to type A and B flu virus and has advantages of anti-drug fast, good tolerance of patient and high safety, and is used for the prevention and treatment of flu.
  • oseltamivir phosphate is a therapeutic drug for preventing and controlling pandemic of flu used by World Health Organization and Chinese Ministry of Public Health, and also a drug reserved for national strategy to prevent and control pandemic of flu in China and other countries in the world.
  • oseltamivir preparation form in China is capsule, its unit dose is 98.5 mg/granule (which contain oseltamivir 75 mg), according to body weight-dose table recommended to children over 1 year old, oseltamivir phosphate is taken in a dose as listed as follows:
  • Body weight Recommended dose (taken for 5 days) ⁇ 15 kg 30 mg, twice per day >15-23 kg 45 mg, twice per day >23-40 kg 60 mg, twice per day >40 kg 75 mg, twice per day
  • capsule dosage form is not suitable for these special human. Therefore, it is necessary to develop new dosage form of oseltamivir phosphate suitable for old people, children and flu gravis patients.
  • the inventor has developed oseltamivir phosphate granules having a plurality of advantages; for example, granules are water soluble, which can be taken after mixing with water, and thereby suitable for children and patients that are difficult to swallow capsules.
  • the administration dose can be conveniently selected according to the age and body weight of patients.
  • the preparation is simple and low cost.
  • the present invention at one aspect relates to oseltamivir phosphate granules.
  • Said granules comprise oseltamivir phosphate, at least one diluent, at least one binder and optionally edible flavouring essence, sweetener and/or edible pigment.
  • the oseltamivir phosphate granules according to the present invention comprise 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, and optionally 1.0-5.0 wt. % edible flavouring essence, sweetener and/or edible pigment.
  • the sum of various ingredients is equal to or less than 100%.
  • the present invention at another aspect provides a method for the preparation of oseltamivir phosphate granules, which comprises the steps of mixing oseltamivir phosphate, diluent, binder and optionally edible flavoring essence, sweetener and/or edible pigment, preparing soft material, passing through sieve, pelletizing, and finishing granules.
  • oseltamivir phosphate granules per gram comprise 0.0197-0.198 g oseltamivir phosphate, and diluent, binder and optionally edible flavoring essence, sweetener and/or edible pigment.
  • the oseltamivir phosphate granules of the present invention comprise:
  • the sum of the various ingredients is equal to or less than 100%.
  • oseltamivir phosphate granules per unit dose contain 15-150 mg of oseltamivir, as active ingredient, for example, per unit dose contains 15 mg, 25 mg, 30 mg, 45 mg, 60 mg, 75 mg or 90 mg of oseltamivir, preferably 15 mg and 25 mg of oseltamivir.
  • the granules of the present invention are prepared into a soft material with 30-55 v/v %, preferably 40 v/v % of ethanol aqueous solution as wetting agent. Therefore, the obtained granules have appropriate degree of tightness, good fluidity, exact package amount, uniform content, and high release degree.
  • the diluent used in oseltamivir phosphate granules is selected from one or two of powdered sugar, dextrin, sorbitol.
  • Said powdered sugar includes but is not limited sucrose, glucose, Aspartame, Steviosin, etc. sugar in common sense; said diluent can simultaneously have action of modifying the taste;
  • the binder is selected from one or more of carboxymethylcellulose sodium, methylcellulose, povidone, tragacanth, acacia, the binder can have simultaneously suspension promotion;
  • the sweetener is selected from sucrose, glucose, Aspartame or Steviosin.
  • the oseltamivir phosphate granules of the present invention are prepared by following steps:
  • the granules of the present invention are in the form of unit dose, they can be packed in a bottle or in a bag.
  • Per bottle or bag contains 0.6-6 g granules.
  • the formulation is packed using aluminum and plastic composite film, per bag contains 0.6-6 g granules.
  • the granules is water-soluble; the resultant aqueous solution is clear and transparent and good taste; the children exhibits high compliableness to it, and meanwhile the bioavailability of oseltamivir phosphate is enhanced;
  • the granules is convenient in administration, dissolves immediately in mouth, it can be taken by buccal or with water;
  • Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve.
  • oseltamivir phosphate, povidone k30 and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40 v/v % ethanol aqueous solution, passed through 14 mesh sieve and pelletized.
  • the wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder.
  • the content of the primary drug of the granules and moisture were determined, and the package amount was determined.
  • the obtained granules were packed with aluminum plastic composite film into packages of 0.6 g/per unit dose, which contains 15 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 30 mg or 45 mg of oseltamivir.
  • Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve.
  • oseltamivir phosphate, povidone k30 and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40 v/v % ethanol aqueous solution, passed through 14 mesh sieve and pelletized.
  • the wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder.
  • the content of the primary drug of the granules and moisture were determined, and the package amount was determined.
  • the obtained granules were packed with aluminum plastic composite film into packages of 1.0 g/per unit dose, which contains 15 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 30 mg or 45 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg or 45 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1.2 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg or 45 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg or 75 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg or 90 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg or 150 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg or 150 mg of oseltamivir.
  • Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve.
  • oseltamivir phosphate, carboxymethylcellulose sodium and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40% ethanol aqueous solution, passed through 14 mesh sieve and pelletized.
  • the wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder.
  • the content of the primary drug of the granules and moisture were determined, and the package amount was determined.
  • the obtained granules were packed with aluminum plastic composite film into packages of 1.0 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 50 mg or 75 mg of oseltamivir.
  • Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve.
  • oseltamivir phosphate, methylcellulose sodium and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40 v/v % ethanol aqueous solution, passed through 14 mesh sieve and pelletized.
  • the wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder.
  • the content of the primary drug of the granules and moisture were determined, and the package amount was determined.
  • the obtained granules were packed with aluminum plastic composite film into packages of 1.0 g/per unit dose, which contains 25 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 50 mg or 75 mg of oseltamivir.
  • Example 2 The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 150 mg of oseltamivir.
  • the obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg, or 90 mg of oseltamivir.
  • Example 1 When the granules obtained in Example 1 were prepared with water into a solution containing 5 mg/ml of oseltamivir, the pH was tested to be about 5.4, the solution was neutral to weakly acid solution, had no stimulus to human body, had good taste, and was in favor of use of patients.
  • the sum of No. 1 oversize product and No. 5 undersize product should not exceed 15% of test samples.
  • the test results showed that aforesaid granules samples were all in conformity with the requirements of Chinese Pharmacopoeia to completely guarantee the uniformity of the particle size of the granules, so that the quality of the granules was not influenced by damp caking or breaking during transportation and storage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, optionally 1.0-5.0 wt. % edible flavoring essence, sweetener and/or edible pigment. It is prepared by using 30-55 v/v % aqueous ethanol solution as moistening agent. The granules prepared by the formulation and method according to the present invention have good uniformity and stability and are water-soluble. The administration dosage of the granules can be conveniently selected based on the age and body weight of patients. The oseltamivir phosphate granule is suitable for administering to old people, children and flu gravis patients and those patients that swallow inconveniently or difficulty. The preparation of the granule is simple and low in production cost.

Description

CROSS REFERENCE TO RELATED APPLICATION
This application is National Phase Patent Application and claims the priority of International Application Number PCT/CN2006/002043, filed on Aug. 11, 2006, which claims priority of Chinese Patent Application Number 200610066995.7, filed on Apr. 4, 2006.
TECHNICAL FIELD
The present invention relates to oseltamivir phosphate granules and preparation method thereof.
BACKGROUND ART
Neuramidinase (NA) inhibitor is an anti-flu virus drug that has been developed recently. As a recently developed NA inhibitor, oseltamivir phosphate is effective to type A and B flu virus and has advantages of anti-drug fast, good tolerance of patient and high safety, and is used for the prevention and treatment of flu. oseltamivir phosphate is a therapeutic drug for preventing and controlling pandemic of flu used by World Health Organization and Chinese Ministry of Public Health, and also a drug reserved for national strategy to prevent and control pandemic of flu in China and other countries in the world.
At present, commercial oseltamivir preparation form in China is capsule, its unit dose is 98.5 mg/granule (which contain oseltamivir 75 mg), according to body weight-dose table recommended to children over 1 year old, oseltamivir phosphate is taken in a dose as listed as follows:
Body weight Recommended dose (taken for 5 days)
≦15 kg 30 mg, twice per day
>15-23 kg 45 mg, twice per day
>23-40 kg 60 mg, twice per day
>40 kg 75 mg, twice per day
Clearly, due to large dose, the capsule cannot be exactly administered to Children patients especially lower age children, and thereby the safety of administration cannot be guaranteed; on the other hand, since old people, children and flu gravis patients swallow inconveniently or difficulty, capsule dosage form is not suitable for these special human. Therefore, it is necessary to develop new dosage form of oseltamivir phosphate suitable for old people, children and flu gravis patients.
SUMMARY OF THE INVENTION
The inventor has developed oseltamivir phosphate granules having a plurality of advantages; for example, granules are water soluble, which can be taken after mixing with water, and thereby suitable for children and patients that are difficult to swallow capsules. The administration dose can be conveniently selected according to the age and body weight of patients. Moreover, the preparation is simple and low cost.
Hence, the present invention at one aspect relates to oseltamivir phosphate granules. Said granules comprise oseltamivir phosphate, at least one diluent, at least one binder and optionally edible flavouring essence, sweetener and/or edible pigment.
Particularly, the oseltamivir phosphate granules according to the present invention comprise 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, and optionally 1.0-5.0 wt. % edible flavouring essence, sweetener and/or edible pigment. The sum of various ingredients is equal to or less than 100%.
The present invention at another aspect provides a method for the preparation of oseltamivir phosphate granules, which comprises the steps of mixing oseltamivir phosphate, diluent, binder and optionally edible flavoring essence, sweetener and/or edible pigment, preparing soft material, passing through sieve, pelletizing, and finishing granules.
According to one embodiment of the present invention, oseltamivir phosphate granules per gram comprise 0.0197-0.198 g oseltamivir phosphate, and diluent, binder and optionally edible flavoring essence, sweetener and/or edible pigment.
According to another embodiment of the present invention, the oseltamivir phosphate granules of the present invention comprise:
Oseltamivir phosphate 1.97-19.8 wt. %
Diluent 75.0-97.5 wt. %
Binder 0.1-5.0 wt. %
Optionally 1.0-5.0 wt. % edible flavouring essence, sweetener and/or edible pigment.
The sum of the various ingredients is equal to or less than 100%.
According to further embodiment of the present invention, oseltamivir phosphate granules per unit dose contain 15-150 mg of oseltamivir, as active ingredient, for example, per unit dose contains 15 mg, 25 mg, 30 mg, 45 mg, 60 mg, 75 mg or 90 mg of oseltamivir, preferably 15 mg and 25 mg of oseltamivir.
The granules of the present invention are prepared into a soft material with 30-55 v/v %, preferably 40 v/v % of ethanol aqueous solution as wetting agent. Therefore, the obtained granules have appropriate degree of tightness, good fluidity, exact package amount, uniform content, and high release degree.
According to the present invention, the diluent used in oseltamivir phosphate granules is selected from one or two of powdered sugar, dextrin, sorbitol. Said powdered sugar includes but is not limited sucrose, glucose, Aspartame, Steviosin, etc. sugar in common sense; said diluent can simultaneously have action of modifying the taste; the binder is selected from one or more of carboxymethylcellulose sodium, methylcellulose, povidone, tragacanth, acacia, the binder can have simultaneously suspension promotion; the sweetener is selected from sucrose, glucose, Aspartame or Steviosin.
The more preferred formulations according to the present invention are demonstrated in Examples.
The oseltamivir phosphate granules of the present invention are prepared by following steps:
1) drying oseltamivir phosphate, diluent and binder at 40-60° C. for 4 hours, crushing and passing through 100 mesh sieve;
2) exactly weighing oseltamivir phosphate, diluent and binder in formation amount, optically adding edible flavouring essence, mixing uniformly by equivalent increase method to give a mixture powder;
3) preparing soft material with 30-55 v/v % ethanol aqueous solution, passing through 14 mesh sieve and pelletizing;
4) drying the wet granules at 45-60° C. completely, finishing the granules by passing through 14 mesh sieve to give dried granules;
5) passing the dried granules through No. 5 sieve to remove fine powders, determining the content of the primary pharmaceutical of the granules and moisture, defining package amount, packing; or mixing the dried granules and edible pigments uniformly and packing to give oseltamivir phosphate granules.
The granules of the present invention are in the form of unit dose, they can be packed in a bottle or in a bag. Per bottle or bag contains 0.6-6 g granules. Preferably, the formulation is packed using aluminum and plastic composite film, per bag contains 0.6-6 g granules.
It has been found by testing the obtained granules that the granules of the present invention (especially the granules prepared by the preferred formulation) have following advantages:
(1) appropriate degree of tightness, good fluidity, exact package amount, uniform content, and high release degree;
(2) good stability of granules, long storage time;
(3) the granules is water-soluble; the resultant aqueous solution is clear and transparent and good taste; the children exhibits high compliableness to it, and meanwhile the bioavailability of oseltamivir phosphate is enhanced;
(4) the granules is convenient in administration, dissolves immediately in mouth, it can be taken by buccal or with water;
(5) the production process is simple and low cost;
(6) the determination of administration dose of children's patients is easy.
EMBODIMENTS Example 1 Preparation of Oseltamivir Phosphate Granules in 15 mg Specification
Ingredients Weight
oseltamivir phosphate 19.7 g
(based on dried product) (containing 15 g of oseltamivir)
Sucrose 568.3 g
Povidone k30 12 g
Total amount 600 g
Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve. oseltamivir phosphate, povidone k30 and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40 v/v % ethanol aqueous solution, passed through 14 mesh sieve and pelletized. The wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder. The content of the primary drug of the granules and moisture were determined, and the package amount was determined. The obtained granules were packed with aluminum plastic composite film into packages of 0.6 g/per unit dose, which contains 15 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 30 mg or 45 mg of oseltamivir.
Example 2 Preparation of Oseltamivir Phosphate Granules in 15 mg Specification
Ingredients Weight
oseltamivir phosphate 19.7 g
(based on dried product) (containing 15 g of oseltamivir)
Sucrose 968.3 g
Povidone k30 12 g
Total amount 1000 g
Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve. oseltamivir phosphate, povidone k30 and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40 v/v % ethanol aqueous solution, passed through 14 mesh sieve and pelletized. The wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder. The content of the primary drug of the granules and moisture were determined, and the package amount was determined. The obtained granules were packed with aluminum plastic composite film into packages of 1.0 g/per unit dose, which contains 15 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 30 mg or 45 mg of oseltamivir.
Example 3 Preparation of Oseltamivir Phosphate Granules in 25 mg Specification
Ingredients Weight
oseltamivir phosphate 32.83 g
(based on dried product) (containing 25 g of oseltamivir)
Sucrose 947.17 g
Povidone 20 g
Total amount 1000 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg or 45 mg of oseltamivir.
Example 4 Preparation of Oseltamivir Phosphate Granules in 25 mg Specification
Ingredients Weight
oseltamivir phosphate 39.4 g
(based on dried product) (containing 30 g of oseltamivir)
Sucrose 1136.6 g
Povidone 24 g
Total amount 1200 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1.2 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg or 45 mg of oseltamivir.
Example 5 Preparation of Oseltamivir Phosphate Granules in 25 mg Specification
Ingredients Weight
oseltamivir phosphate 59.1 g
(based on dried product) (containing 45 g of oseltamivir)
Sucrose 1704.9 g
Povidone 36 g
Total amount 1800 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg or 75 mg of oseltamivir.
Example 6 Preparation of Oseltamivir Phosphate Granules in 25 mg Specification
Ingredients Weight
oseltamivir phosphate 78.8 g
(based on dried product) (containing 60 g of oseltamivir)
Sucrose 2273.2 g
Povidone 48 g
Total amount 2400 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg or 90 mg of oseltamivir.
Example 7 Preparation of Oseltamivir Phosphate Granules in 25 mg Specification
Ingredients Weight
oseltamivir phosphate 98.49 g
(based on dried product) (containing 75 g of oseltamivir)
Sucrose 2841.51 g
Povidone 60 g
Total amount 3000 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg or 150 mg of oseltamivir.
Example 8 Preparation of Oseltamivir Phosphate Granules in 25 ng Specification
Ingredients Weight
oseltamivir phosphate 197.2 g
(based on dried product) (containing 150 g of oseltamivir)
Sucrose 5683.6 g
Povidone 120 g
Total amount 6000 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg or 150 mg of oseltamivir.
Example 9 Preparation of Oseltamivir Phosphate Granules in 15 mg Specification
Ingredients Weight
oseltamivir phosphate 32.83 g
(based on dried product) (containing 25 g of oseltamivir)
Sucrose 947.17 g
Carboxymethylcellulose sodium 20 g
Total amount 1000 g
Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve. oseltamivir phosphate, carboxymethylcellulose sodium and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40% ethanol aqueous solution, passed through 14 mesh sieve and pelletized. The wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder. The content of the primary drug of the granules and moisture were determined, and the package amount was determined. The obtained granules were packed with aluminum plastic composite film into packages of 1.0 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 50 mg or 75 mg of oseltamivir.
Example 10 Preparation of Oseltamivir Phosphate Granules in 25 mg Specification
Ingredients Weight
oseltamivir phosphate 32.83 g
(based on dried product) (containing 25 g of oseltamivir)
Sucrose 947.17 g
Methylcellulose sodium 20 g
Total amount 1000 g
Oseltamivir phosphate and adjuvants were crushed to pass through 100 mesh sieve. oseltamivir phosphate, methylcellulose sodium and sucrose were weighed exactly in an amount in the formulation, and mixed uniformly by equivalent increase method; the mixture was prepared into a soft material with 40 v/v % ethanol aqueous solution, passed through 14 mesh sieve and pelletized. The wet granules were dried at 45-60° C. in an oven, finished by passing through 14 mesh sieve, sieved using No. 5 sieve to remove fine powder. The content of the primary drug of the granules and moisture were determined, and the package amount was determined. The obtained granules were packed with aluminum plastic composite film into packages of 1.0 g/per unit dose, which contains 25 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 50 mg or 75 mg of oseltamivir.
Example 11 Preparation of Oseltamivir Phosphate Granules in 150 mg Specification
Ingredients Weight
oseltamivir phosphate 197.2 g
(based on dried product) (containing 150 g of oseltamivir)
Sucrose 752.8 g
Povidone 50 g
Total amount 1000 g
The preparation method was described as in Example 1. The obtained granules were packed with aluminum plastic composite film into packages of 1 g/per unit dose, which contains 150 mg of oseltamivir.
The obtained granules can also be packed into unit package containing 15 mg, 30 mg, 45 mg, 60 mg, 75 mg, or 90 mg of oseltamivir.
Example 12 Test of Solubility and Dispersibility of Oseltamivir Phosphate
When the granules obtained in Example 1 were prepared with water into a solution containing 5 mg/ml of oseltamivir, the pH was tested to be about 5.4, the solution was neutral to weakly acid solution, had no stimulus to human body, had good taste, and was in favor of use of patients.
According to the requirements of Chinese Pharmacopoeia, 2005 edition, Part 2, Annex IX B, the second method (double sieving method), the sum of No. 1 oversize product and No. 5 undersize product should not exceed 15% of test samples. The test results showed that aforesaid granules samples were all in conformity with the requirements of Chinese Pharmacopoeia to completely guarantee the uniformity of the particle size of the granules, so that the quality of the granules was not influenced by damp caking or breaking during transportation and storage.
10 g of said granules samples was added with 200 ml of hot water, stirred for 5 min, the solubility of the samples was observed. The test results showed that the samples dissolved completely, no foreign matters appeared, in conformity with the requirements of Chinese Pharmacopoeia, 2005 edition, Part 2, Annex IN. The prepared soluble oseltamivir phosphate granules can completely disperse or dissolve in water, so as to ensure the bioavailability of the granules and be convenient for the use of patients.

Claims (12)

What is claimed is:
1. Oseltamivir phosphate granules, comprising:
oseltamivir phosphate at 3.28 wt. %; sucrose at 94.72 wt. %; and povidone k30 at 2.00 wt. %.
2. The oseltamivir phosphate granules of claim 1, wherein per unit dose the oseltamivir phosphate granules contain 15 mg or 25 mg of oseltamivir.
3. A method for preparing the oseltamivir phosphate granules of claim 1, comprising:
drying the oseltamivir phosphate, the sucrose, and the povidone k30 at 40-60° C. for 4 hours to form dried components;
crushing the dried components through a 100 mesh sieve;
exactly weighing the oseltamivir phosphate, the sucrose, and the povidone k30 in formulation amount, optionally adding an edible flavoring essence;
mixing uniformly by equivalent increase method to form a mixture powder;
adding 30-55 v/v % of ethanol aqueous solution to the mixture powder to form a soft material;
passing the soft material through a 14 mesh sieve to form a pellet of wet granules;
drying the pellet of wet granules at 45-60° C. completely and passing through a 14 mesh sieve to form dried granules; and
sieving the dried granules to remove fine powder;
determining the content of a primary drug in the granules and moisture; and
determining package amount, packing or mixing the dried granules and edible pigment uniformly and packing to prepare the oseltamivir phosphate granules.
4. Oseltamivir phosphate granules, comprising:
oseltamivir phosphate at 1.97 wt. %; sucrose at 96.83 wt. %; and povidone k30 at 1.20 wt. %.
5. The oseltamivir phosphate granules of claim 4, wherein per unit dose the oseltamivir phosphate granules contain 15 mg or 25 mg of oseltamivir.
6. A method for preparing the oseltamivir phosphate granules of claim 4, comprising:
drying the oseltamivir phosphate, the sucrose, and the povidone k30 at 40-60° C. for 4 hours to form dried components;
crushing the dried components through a 100 mesh sieve;
exactly weighing the oseltamivir phosphate, the sucrose, and the povidone k30 in formulation amount, optionally adding an edible flavoring essence;
mixing uniformly by equivalent increase method to form a mixture powder;
adding 30-55 v/v % of ethanol aqueous solution to the mixture powder to form a soft material;
passing the soft material through a 14 mesh sieve to form a pellet of wet granules;
drying the pellet of wet granules at 45-60° C. completely and passing through a 14 mesh sieve to form dried granules; and
sieving the dried granules to remove fine powder;
determining the content of a primary drug in the granules and moisture; and
determining package amount, packing or mixing the dried granules and edible pigment uniformly and packing to prepare the oseltamivir phosphate granules.
7. Oseltamivir phosphate granules, comprising:
oseltamivir phosphate at 3.28 wt. %; sucrose at 94.72 wt. %; and carboxymethylcellulose sodium at 2.00 wt. %.
8. The oseltamivir phosphate granules of claim 7, wherein per unit dose the oseltamivir phosphate granules contain 15 mg or 25 mg of oseltamivir.
9. A method for preparing the oseltamivir phosphate granules of claim 7, comprising:
drying the oseltamivir phosphate, the sucrose, and the carboxymethylcellulose sodium at 40-60° C. for 4 hours to form dried components;
crushing the dried components through a 100 mesh sieve;
exactly weighing the oseltamivir phosphate, the sucrose, and the carboxymethylcellulose sodium in formulation amount, optionally adding an edible flavoring essence;
mixing uniformly by equivalent increase method to form a mixture powder;
adding 30-55 v/v % of ethanol aqueous solution to the mixture powder to form a soft material;
passing the soft material through a 14 mesh sieve to form a pellet of wet granules;
drying the pellet of wet granules at 45-60° C. completely and passing through a 14 mesh sieve to form dried granules; and
sieving the dried granules to remove fine powder;
determining the content of a primary drug in the granules and moisture; and
determining package amount, packing or mixing the dried granules and edible pigment uniformly and packing to provide the oseltamivir phosphate granules.
10. Oseltamivir phosphate granules, comprising:
oseltamivir phosphate at 3.28 wt. %; sucrose at 94.72 wt. %; and methylcellulose sodium at 2.00 wt. %.
11. The oseltamivir phosphate granules of claim 10, wherein per unit dose the oseltamivir phosphate granules contain 15 mg or 25 mg of oseltamivir.
12. A method for preparing the oseltamivir phosphate granules of claim 10, comprising:
drying the oseltamivir phosphate, the sucrose, and the methylcellulose sodium at 40-60° C. for 4 hours to form dried components;
crushing the dried components through a 100 mesh sieve;
exactly weighing the oseltamivir phosphate, the sucrose, and the methylcellulose sodium in formulation amount, optionally adding an edible flavoring essence;
mixing uniformly by equivalent increase method to form a mixture powder;
adding 30-55 v/v % of ethanol aqueous solution to the mixture powder to form a soft material;
passing the soft material through a 14 mesh sieve to form a pellet of wet granules;
drying the pellet of wet granules at 45-60° C. completely and passing through a 14 mesh sieve to form dried granules; and
sieving the dried granules to remove fine powder;
determining the content of a primary drug in the granules and moisture; and
determining package amount, packing or mixing the dried granules and edible pigment uniformly and packing to prepare the oseltamivir phosphate granules.
US12/225,935 2006-04-04 2006-08-11 Oseltamivir phosphate granule and preparation method thereof Active 2028-07-20 US9034382B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200610066995 2006-04-04
CN200610066995.7 2006-04-04
CN2006100669957A CN1820744B (en) 2006-04-04 2006-04-04 Oseltamivir phosphate granula and its preparing method
PCT/CN2006/002043 WO2007112619A1 (en) 2006-04-04 2006-08-11 Oseltamivir phosphate granule and preparation mehtod thereof

Publications (2)

Publication Number Publication Date
US20090176877A1 US20090176877A1 (en) 2009-07-09
US9034382B2 true US9034382B2 (en) 2015-05-19

Family

ID=36922416

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/225,935 Active 2028-07-20 US9034382B2 (en) 2006-04-04 2006-08-11 Oseltamivir phosphate granule and preparation method thereof

Country Status (7)

Country Link
US (1) US9034382B2 (en)
EP (1) EP2005945B1 (en)
JP (1) JP5222841B2 (en)
KR (1) KR101303325B1 (en)
CN (1) CN1820744B (en)
ES (1) ES2604778T3 (en)
WO (1) WO2007112619A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183583A1 (en) * 2006-02-20 2012-09-27 Chugai Pharmaceutical Co Ltd Pharmaceutical composition comprising oseltamivir phosphate
CN1820744B (en) 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 Oseltamivir phosphate granula and its preparing method
WO2010143207A1 (en) 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
CN103315965B (en) * 2013-07-11 2015-08-05 河南中帅医药科技股份有限公司 A kind of oral administration solid granule being applicable to infant and child and preparation method thereof
CN104940125A (en) * 2014-03-28 2015-09-30 广东东阳光药业有限公司 Solid preparation of oseltamivir phosphate
KR20160002177A (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Pharmaceutical composition comprising oseltamivir free base
CN104138355A (en) * 2014-08-06 2014-11-12 广东东阳光药业有限公司 Oseltamivir phosphate dry suspension and preparation method thereof
KR20160038837A (en) * 2014-09-30 2016-04-07 한미약품 주식회사 Granules containing oseltamivir, capsules comprising the granules, and a process for the preparation thereof
WO2016088010A1 (en) * 2014-12-01 2016-06-09 Lupin Atlantis Holdings Sa Oseltamivir compositions
KR20160117070A (en) * 2015-03-31 2016-10-10 한미약품 주식회사 An oral solid formulation containing oseltamivir and a process for the preparation thereof
CN106236728A (en) * 2015-06-03 2016-12-21 广东东阳光药业有限公司 A kind of oseltamivir phosphate decentralized capsule and preparation method thereof
WO2018004261A1 (en) * 2016-06-30 2018-01-04 한미약품 주식회사 Oseltamivir-containing solid preparation for oral administration and method for preparing same
JP6778051B2 (en) * 2016-08-18 2020-10-28 沢井製薬株式会社 Oseltamivir phosphate-containing pharmaceutical composition
KR20200106607A (en) * 2019-03-05 2020-09-15 주식회사 코아팜바이오 A pharmaceutical composition comprising oseltamivir
CN113603606A (en) * 2021-08-25 2021-11-05 北京睿悦生物医药科技有限公司 Preparation method of oseltamivir phosphate dry suspension impurity
CN114262278B (en) * 2021-12-20 2023-09-26 北京阳光诺和药物研究股份有限公司 Method for preparing oseltamivir phosphate

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
JPH10502114A (en) 1994-06-28 1998-02-24 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン Method for producing granules containing multiple enzymes
US20020018812A1 (en) 2000-06-27 2002-02-14 Patrick Busson Process for preparing a pharmaceutical composition
US20040062801A1 (en) * 2001-07-17 2004-04-01 Joaquina Faour Drug delivery device containing neuraminidase inhibitor and an H1 antagonist
US20040198838A1 (en) * 2001-07-20 2004-10-07 Rainer Alles Pharmaceutical compositions containig terbinafin and use thereof
JP2005060265A (en) 2003-08-08 2005-03-10 Shionogi & Co Ltd Dry syrup preparation containing loratadine
WO2007097325A1 (en) 2006-02-20 2007-08-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
US20090176877A1 (en) 2006-04-04 2009-07-09 Song Li Oseltamivir phoshate granule and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310999A (en) * 2000-02-29 2001-09-05 布里斯托尔-迈尔斯斯奎布公司 Low dose Etikavi Prepn. and the use thereof
EP1602730A3 (en) * 2004-06-04 2006-01-25 DSM IP Assets B.V. Biosynthetic production of 4-amino-4-deoxychorismate (ADC) and [3R,4R]-4-amino-3-hydroxycyclohexa-1,5-diene-1-carboxylic acid (3,4-CHA)

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10502114A (en) 1994-06-28 1998-02-24 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン Method for producing granules containing multiple enzymes
US5972668A (en) 1994-06-28 1999-10-26 Henkel Kommanditgesellschaft Auf Aktien Production of multi-enzyme granules
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US20060134205A1 (en) 2000-06-27 2006-06-22 Patrick Busson Process for preparing a pharmaceutical composition
US20020018812A1 (en) 2000-06-27 2002-02-14 Patrick Busson Process for preparing a pharmaceutical composition
US20030039614A1 (en) 2000-06-27 2003-02-27 Patrick Busson Process for preparing a pharmaceutical composition
US6534087B2 (en) 2000-06-27 2003-03-18 Hoffmann-La Roche Inc. Process for preparing a pharmaceutical composition
CN1438880A (en) 2000-06-27 2003-08-27 霍夫曼-拉罗奇有限公司 Method for preparing a composition
US7074431B2 (en) 2000-06-27 2006-07-11 Hoffmann-La Roche Inc. Process for preparing a pharmaceutical composition
US20040062801A1 (en) * 2001-07-17 2004-04-01 Joaquina Faour Drug delivery device containing neuraminidase inhibitor and an H1 antagonist
US20040198838A1 (en) * 2001-07-20 2004-10-07 Rainer Alles Pharmaceutical compositions containig terbinafin and use thereof
JP2005060265A (en) 2003-08-08 2005-03-10 Shionogi & Co Ltd Dry syrup preparation containing loratadine
WO2007097325A1 (en) 2006-02-20 2007-08-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
EP1987825A1 (en) 2006-02-20 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
US20100222427A1 (en) 2006-02-20 2010-09-02 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
US20090176877A1 (en) 2006-04-04 2009-07-09 Song Li Oseltamivir phoshate granule and preparation method thereof
JP2009532390A (en) 2006-04-04 2009-09-10 インスティチュート オブ ファーマコロジー アンド トクシコロジー アカデミー オブ ミリタリー メディカル サイエンス、 ピー．エル．エー．チャイナ Oseltamivir phosphate granule and preparation method thereof

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Emea; "Tamiflu: EPAR-Scientific Discussion"; Tamiflu oseltamivir European public assessment report: Assessment history; Oct. 21, 2005, 25pp.
Examination Report dated Aug. 7, 2013 issued in corresponding European Patent Application No. 06 775 361.6, 5pp.
Extended European Search Report for corresponding EP Application No. 06775361.6, dated Nov. 12, 2012, 6pp.
International Search Report, dated Jan. 11, 2007, corresponding to PCT/CN2006/002043.
Japanese Language article, 1971, pp. 50-55.
Japanese Language Ingredients, 1994, pp. 32, 99, 100, 124-126, and 138.
Notice of Allowance dated Nov. 12, 2010, with partial English translation, for corresponding Chinese Patent Application No. 200610066995.7.
Office Action dated Jun. 11, 2010, with partial English translation, for corresponding Chinese Patent Application No. 200610066995.7.
Office Action dated Mar. 1, 2010, with partial English translation, for corresponding Chinese Patent Application No. 200610066995.7.
Office Action dated Sep. 4, 2009, with partial English translation, for corresponding Chinese Patent Application No. 200610066995.7.
Office action for corresponding Japanese Patent Application No. 2009-503391, dated Apr. 17, 2012, 4pp.
Office action for corresponding Japanese Patent Application No. 2009-503391, dated Sep. 4, 2012.
Oo et al., "Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children", PaediatrDrugs, 2001, vol. 3., issue 3, pp. 229-236. *
Tamiflu Dry Syrup 3%; Anti-influenza medicine; 3pp.
Tamiflu; 2005; pp. 1-6.(Japanese Language).

Also Published As

Publication number Publication date
EP2005945A4 (en) 2012-12-19
CN1820744A (en) 2006-08-23
US20090176877A1 (en) 2009-07-09
KR101303325B1 (en) 2013-09-03
EP2005945A2 (en) 2008-12-24
JP5222841B2 (en) 2013-06-26
CN1820744B (en) 2011-01-26
WO2007112619A1 (en) 2007-10-11
EP2005945A9 (en) 2009-07-01
KR20080109020A (en) 2008-12-16
JP2009532390A (en) 2009-09-10
ES2604778T3 (en) 2017-03-09
EP2005945B1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
US9034382B2 (en) Oseltamivir phosphate granule and preparation method thereof
US20200323776A1 (en) Diclofenac formulations and methods of use
RU2241460C2 (en) Cefuroxime axetyl-containing pharmaceutical composition with masked bitter taste
US20100183730A1 (en) High dose composition of ursodeoxycholic acid
CZ294434B6 (en) Medicament for treating bacterial infection in pediatric patients
BG66212B1 (en) Formulation
CN111617042A (en) Composite calcium carbonate vitamin D3Water-free swallow granule and preparation method thereof
JPH0296526A (en) Powdery or granular drug preparation
EP2481395A1 (en) Sachet, effervescent tablet and dry syrup of otilonium
JP2002542283A (en) Pharmaceutical formulations
WO2020208398A1 (en) Pharmaceutical composition comprising memantine and donepezil for use in the treatment of alzheimer's disease
MXPA04006159A (en) Ribavirin granulate for producing coated tablets.
CN101062047B (en) Combination including isoglycyrrhizinate and oxymatrine and the purpose thereof
KR20130110669A (en) Pharmaceutical composition comprising branched chain amino acids as active ingredients and the preparation method thereof
EP2508187A1 (en) Triflusal powder containing cyclodextrin as a stabilizing agent
CN113038933A (en) Oral pharmaceutical preparation containing ibuprofen
JPWO2021062061A5 (en)
SK285966B6 (en) Effervescent tablet comprising magnesium and method for the preparation thereof
CZ11407U1 (en) A pharmaceutical composition adapted for pediatric administration

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY O

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, SONG;ZHONG, WU;XIAO, JUNHAI;AND OTHERS;REEL/FRAME:021854/0582

Effective date: 20081104

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8